Taxus Pharmaceuticals Holdings Inc. (TXSP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
245-16 HORACE HARDING EXPRESSWAY, LITTLE NECK, NY 11362 |
| State of Incorp. | NY |
| Fiscal Year End | June 30 |
| Industry (SIC) | 5912 - Drug Stores and Proprietary Stores (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | 6/30/2017 Q4 | 3/31/2017 Q3 | 12/31/2016 Q2 | 9/30/2016 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,836 | 5,836 | 5,856 | 5,959 | 6,344 | 6,873 | |||
| Cash and cash equivalents | 5,836 | 5,836 | 5,856 | 5,959 | 6,344 | 6,873 | |||
| Inventory, net of allowances, customer advances and progress billings | 20,763 | 21,035 | |||||||
| Inventory | 20,763 | 21,035 | |||||||
| Total current assets: | 5,836 | 5,836 | 5,856 | 5,959 | 27,107 | 27,908 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | (2,500) | ||||||||
| Other undisclosed noncurrent assets | 5,500 | 3,000 | 3,000 | 3,000 | 3,000 | ||||
| Total noncurrent assets: | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | ||||
| TOTAL ASSETS: | 5,836 | 8,836 | 8,856 | 8,959 | 30,107 | 30,908 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 47,015 | 74,015 | 62,515 | 91,015 | 93,515 | 82,015 | |||
| Accrued liabilities | 47,015 | 74,015 | 62,515 | 91,015 | 93,515 | 82,015 | |||
| Total current liabilities: | 47,015 | 74,015 | 62,515 | 91,015 | 93,515 | 82,015 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 47,015 | 74,015 | 62,515 | 91,015 | 93,515 | 82,015 | |||
| Equity | |||||||||
| Equity, attributable to parent | (41,179) | (65,179) | (53,659) | (82,056) | (63,408) | (51,107) | |||
| Common stock | 815 | 815 | 815 | 815 | 815 | 815 | |||
| Additional paid in capital | 676,901 | 648,901 | 648,901 | 587,602 | 573,602 | 573,602 | |||
| Accumulated deficit | (718,895) | (714,895) | (703,375) | (670,473) | (637,825) | (625,524) | |||
| Total equity: | (41,179) | (65,179) | (53,659) | (82,056) | (63,408) | (51,107) | |||
| TOTAL LIABILITIES AND EQUITY: | 5,836 | 8,836 | 8,856 | 8,959 | 30,107 | 30,908 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | 6/30/2017 Q4 | 3/31/2017 Q3 | 12/31/2016 Q2 | 9/30/2016 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 500 | 2 | 363 | 5,488 | ||||
| Cost of revenue | (20,763) | (272) | (4,117) | |||||
| Gross profit: | 500 | (20,761) | 91 | 1,371 | ||||
| Operating expenses | (4,000) | (12,020) | (12,141) | (32,648) | (12,392) | (40,517) | ||
| Operating loss: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
| Loss from continuing operations: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
| Loss before gain (loss) on sale of properties: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
| Net loss available to common stockholders, diluted: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
Comprehensive Income (USD)Annual | Quarterly
| 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | 6/30/2017 Q4 | 3/31/2017 Q3 | 12/31/2016 Q2 | 9/30/2016 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,000) | (11,520) | (32,902) | (32,648) | (12,301) | (39,146) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.